The Arizona Bioscience Company of the Year is on a Mission to Cure the Uncurable Calimmune, Inc., acquired by global biotechnology leader CSL Limited in 2017 and now fully integrated within CSL, is the 2018 the Arizona Bioscience Company of the Year.  

When CSL Limited, the world’s 5th largest biotechnology company, acquired Arizona-based Calimmune in August 2017, the global biotechnology leader’s Chief Executive Officer, Paul Perreault, said, “Calimmune’s scientific accomplishments are impressive.”  Those accomplishments included accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases.  

https://www.azbio.org/the-arizona-bioscience-company-of-the-year-is-on-a-mission-to-cure-the-uncurable

AdviNow Medical’s do-it-yourself kiosk seeks to transform the patient/provider encounter through the use of Artificial Intelligence (AI) and Augmented Reality (AR).  

Using AdviNow Medical’s unique tool, patients are guided through self-administered steps to collect data such as weight, temperature, blood pressure, and blood oxygen, as well as ear, nose and throat images, and chest, lung and abdomen sounds. Follow-up questions are asked until all the information necessary for a clinical differential diagnosis is acquired. The total process typically takes less than 15 minutes. A complete patient work-up is sent to the provider with a breakdown of predicted illnesses and treatment options—giving them key details that enhance the patient visit. Every detail of the encounter is auto-charted and scribed into the electronic medical record, saving the provider valuable time. The AI also sends the medication and/or procedure orders to the appropriate healthcare partner and completes the billing process.   

https://www.azbio.org/advinow-medical-wins-azbio-fast-lane-award

bioSyntagma is a precision medicine company that provides deep data on the uniqueness of each person’s cancer to transform how their cancer is treated.  

The company has developed a device that enables researchers and drug developers to physically map cancer tissues for biological markers that predict the response to treatments and outcomes. 

https://www.azbio.org/biosyntagma-wins-azbio-fast-lane-award

NeoLight is moving from its initial development stage into commercialization and for its commitment to develop innovative products that can help more babies thrive. According to the World Health Organization, six out of 10 infants, and eight out of 10 pre-term infants, develop jaundice by default. If not addressed, neonatal jaundice can affect some of the baby’s brain cells. This may cause the baby to be less active. In rare cases, a baby may develop seizures (convulsions). The effects of this kind of jaundice may also lead to deafness, cerebral palsy and/or other developmental disorders.  

What started off as an Arizona State University spin-out, with $7,000 in funding from the university after winning their Edson student entrepreneurship competition in 2014, has been steadily gaining momentum.  

https://www.azbio.org/neolight-wins-azbio-fast-lane-award

The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery.